THOMAS FRANK E 4

What Happened
Thomas E. Frank, a director of Larimar Therapeutics (LRMR), was granted 55,150 derivative shares (reported as an award/acquisition) on 2026-05-19 at a price of $0.00 per share (no cash paid). This filing reports a grant of equity-based awards rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-19; Form 4 filed 2026-05-20 (appears timely).
• Security: derivative equity award of 55,150 shares; reported price $0.00; total reported value $0.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: awards vest on the earlier of (a) May 19, 2027 or (b) the date of the company’s next annual meeting of stockholders, subject to Mr. Frank’s continued service on the board.
• Transaction code: A (award/grant).

Context
This was a grant of derivative securities (an equity award) rather than an exercise or sale; no shares were sold or bought on the open market and no immediate cash changed hands. Such awards typically vest over time or upon a corporate event and do not necessarily indicate immediate intent to buy or sell stock.